Free tool
FAERS Monitor: Annovera
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209627 or its brand name (Annovera, Ethinyl Estradiol, Segesterone Acetate). Reports on generic versions are filed under their own applications.
Reports
383
Serious
75
20% of reports
Hospitalization
28
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- intermenstrual bleeding44
- off label use36
- vaginal haemorrhage36
- nausea34
- drug ineffective26
- headache23
- vaginal discharge18
- vomiting17
- device expulsion15
- pulmonary embolism13
- depression12
- metrorrhagia12
- migraine12
- abdominal pain11
- dysmenorrhoea11
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2020 | 57 |
| 2021 | 86 |
| 2022 | 87 |
| 2023 | 38 |
| 2024 | 30 |
| 2025 | 52 |
| 2026 | 32 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,776 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intermenstrual bleedingSignal | 44 | 435.8 | 329.6 | 18,513 |
| vaginal dischargeSignal | 18 | 97.8 | 62.3 | 1,628 |
| dysmenorrhoeaSignal | 11 | 45.6 | 25.5 | 436 |
| vaginal haemorrhageSignal | 36 | 45.6 | 33.4 | 1,527 |
| metrorrhagiaSignal | 12 | 38.7 | 22.2 | 404 |
| device expulsionSignal | 15 | 12.7 | 7.7 | 151 |
| pulmonary embolismSignal | 13 | 7.5 | 4.4 | 67 |
| migraineSignal | 12 | 6.9 | 4.0 | 55 |
| depressionSignal | 12 | 2.9 | 1.7 | 13 |
| abdominal painSignal | 11 | 2.6 | 1.5 | 9 |
| nauseaSignal | 34 | 2.4 | 1.7 | 26 |
| off label useSignal | 36 | 2.3 | 1.7 | 25 |
| headacheSignal | 23 | 2.0 | 1.4 | 11 |
| vomiting | 17 | 2.0 | 1.2 | 8 |
| drug ineffective | 26 | 1.1 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.